Navigation Links
Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
Date:9/24/2009

expense category that increased faster than our revenue growth was our planned investment in research and development. We are very pleased to be able to accelerate our R&D spending for Neogen's future, and still report today's exceptional results."

Largely the result of a favorable product mix that included a greater percentage of diagnostic products, Neogen's gross margin increased to 53.4% of sales in its first quarter of the current year, compared to 51.4% of sales in its FY 2009 first quarter. Neogen's operating income for the first quarter equaled 21.5% of the company's quarterly revenues.

"As our consolidated balance sheet data shows, we had an exceptional quarter generating cash, and we now have more than $23 million in cash and investments to pursue a wide variety of growth strategies," said Richard Current, Neogen's chief financial officer. "Our inventories are down in comparison to our prior quarter, as we continue our progress in controlling the level of inventories without impacting sales. Our accounts receivable have increased slightly, but at a pace less than our sales increase. We continue to monitor the financial health of our customers to avoid collection concerns, and have yet to experience significant receivable problems."

Neogen's Food Safety and Animal Safety Divisions posted nearly identical 12% revenue increases in the first quarter compared to the prior year's first quarter. The food safety sales increase was entirely organic, while the year-over-year animal safety increase benefited from the July 2008 acquisition of DuPont cleaners and disinfectants, and the May 2009 acquisition of International Diagnostic Systems (IDS). Acquired IDS products include a number of drug detection diagnostics. Company-wide, Neogen's organic sales grew approximately 9% in the quarter compared to the prior year's first quarter.

The company's quarterly food safety sales improvement w
'/>"/>

SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neogen Acquires Kane Enterprises
2. Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues
3. Neogen Acquires Assets of Rivard Instruments
4. Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues
5. Neogen Launches Quickest Test Available for Tetracyclines in Milk
6. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
7. Webcast Alert: Neogen Corporation Announces 3rd Quarter Results
8. Neogen Reports 34% Increase in Net Income, 20% Increase in Revenues
9. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
10. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
11. Neogen Forms Mexican Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 2015. Biorem,s complete second quarter financial statements and MD&A have been ... except earnings per shareThree-months ended , Six -months endedJune 30 , ... , 2014 Revenue , 4,709 , ... , 1,656 , 56 , 3,188 ...
(Date:8/27/2015)... , August 27, 2015 GlassesOff (OTCBB: ... processing functions in the human vision system, announced today a ... point guard Chris Paul to develop a new ... want to improve their real-life on-court performance. Vision ... whether it is shooting a ball or blocking a pass. ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER ... expertly narrows down the product choices to a manageable shortlist of bench and ... list to models that fit best with the customer’s industry and application. ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... Personalized Medicine, recently presented new data on the relationship of genetics and hypertension ... World Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, which ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... Rapid Production, Increased Bioavailability, MOUNTAIN VIEW, Calif., ... are either incurable or difficult to treat allures ... prized, due to their,therapeutic potential, stem cell therapies ... Stem cell research progresses at a fast pace; ...
... Inc. (Nasdaq: CEPH ) and Eurand NV ... Paragraph IV Certification Notice Letter on October 20, ... to the U.S.,Food and Drug Administration (FDA) by ... a generic version of the 15 mg and,30 ...
... 71% of Evaluable Patients in the Trial,s First Stage ... Achieved Objective Tumor Responses- ... Second Stage-, TUSTIN, Calif., Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... cancer and serious viral,infections, today announced that updated preliminary data from ...
Cached Biology Technology:Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 2Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 2Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 4Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... a novel study, a University of Oklahoma researcher and collaborators ... test the toxicity of water or sediment was resistant to ... is the first to demonstrate that the indicator species may ... entirely unreliable source of information about ecosystem health. ...
... and forest disturbances may have a silver lining for ... a 10-year study that monitored 112 bears in Alberta,s ... and his colleagues found that warmer temperatures and easier ... grizzlies to build more body fat, known to increase ...
... scanners that give scientists a direct line of sight ... Fraser University researchers will use to help Ballard Power ... of these fuel cells in vehicles can substantially reduce ... Nano X-ray Computed Tomography (NXCT) tools will become part ...
Cached Biology News:OU research team finds a common bioindicator resistant to insecticides 2Climate change has silver lining for grizzlies 2Scientists to gain from view inside of fuel cells 2
... dye terminators, template DNA, primers, salts or ... products have proved critical for both standard ... to work with dye terminator cycle sequencing ... The unique uniformity of the magnetic paeticles ...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
X-gal,1g...
RayBio Human Atherosclerosis Antibody Array 1.1 (4) with Accessory, detects 40 inflammatory factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: